美股A股
StockGist

Castle Biosciences, Inc.

CSTLNASDAQ · Healthcare · Medical - Diagnostics & ResearchGARP
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers.
$33.79-2.06%
报价 2026-11-13
市值
$1.04B
EV
$1.07B
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -21.5%
$18.15$43.04

筛选结果

pipeline · 2026-11-13
Keep✗ 高增长✗ Cheap✓ GARP
GARP Pool: growth 10-30%, MC/GP <= 11

爆发潜力

2026-11-13
未命中✗ 收入线✗ EPS 线
财年收入倍数EPSPE
FY+22027-121.2x-0.77 → -0.55—
FY+32028-121.3x-0.77 → -0.01—

毛利率 77% · TTM 收入 $377M · 基数 EPS -0.77(调整后)

电话会信号

辅助标签
Q3 20262026-11-05
扩产上调指引盈利拐点
指引 上调
信心 4
分析师 4

“We expect positive adjusted EBITDA for the fourth quarter, full year 2026 and full year 2027.”

原文引用(3)
  • 扩产:as the volumes grow, we will have to add people in both facilities, Pittsburgh and Scottsdale.
  • 上调指引:We are increasing our full year 2026 total revenue guidance from our prior range of $365 million to $375 million to $385 million to $395 million.
  • 盈利拐点:We also expect adjusted EBITDA for the full year 2027 to be positive.

蓝色标签在暴涨研究中略有区分度;悬停查看口径。

研究结论

还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。

去生成基本面报告 →

历史股价

加载中…

事件

0 条 · 随区间与图例筛选

该区间内无事件。

同行对比

FMP 同行列表 · 2026-05-16
公司市值今日预期营收增速毛利率PEEV/EBITDAP/FCF池
CSTLCastle Biosciences, Inc.$1.04B-2.1%+15.6%77.1%–––GARP
CDNACareDx, Inc$4.09B-2.4%+40.1%71.1%32.6x141.7x71.0x高增长
VIRVir Biotechnology, Inc.$1.71B-17.8%+1488.5%97.2%–––
PSNLPersonalis, Inc.$1.7B-0.9%+19.4%21.2%–––
AMNAMN Healthcare Services, Inc.$1.47B+1.6%+26.5%30.6%17.4x6.4x4.1xCheap GARP
FLGTFulgent Genetics, Inc.$689M-0.8%+3.3%33.8%–––
GERNGeron Corporation$623M-2.7%+26.3%66.7%–––
EVHEvolent Health, Inc.$551.2M+2.7%+40.8%12.9%––31.9x
MYGNMyriad Genetics, Inc.$542.9M-0.4%-4.7%68.8%–––
同行中位数––+26.4%50.3%25.0x74.1x31.9x

研究全文

L2 基本面 memo

尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。

财务报表

Metric
2026-06-30
Q2 2026
2026-03-31
Q1 2026
2025-12-31
Q4 2025
2025-09-30
Q3 2025
2025-06-30
Q2 2025
2025-03-31
Q1 2025
2024-12-31
Q4 2024
2024-09-30
Q3 2024
Revenue$103.5M$83.7M$87M$83M$86.2M$88M$86.3M$85.8M
Gross Margin77.1%75.5%79%77.5%79.5%81.4%81.3%81.8%
Operating Margin-3%-22%-4.4%-8.2%-4.9%-31.7%4.7%5.9%
Net Income$-2.1M$-14.5M$-2.3M$-501,000$4.5M$-25.8M$9.6M$2.3M
Diluted EPS-0.07-0.49-0.08-0.020.15-0.90.320.08
Operating Cash Flow$15.2M$-22.1M$26.9M$22.6M$20.8M$-6M$24.4M$23.3M

研究材料